Indeed, Ozempic and Wegovy may well be in the news in the coming months—if Trump imposes the massive tariffs on Denmark that ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Metsera's lead asset is MET-097i, billed as an ultra-long-acting GLP-1 receptor agonist with a profile that could challenge ...

An estimated 3.4 million Brits meet the criteria to receive a prescription for Wegovy and Mounjaro which would cost ...

We meet some of the first NHS patients, as expert says funding everyone eligible would "bankrupt" the service.

There’s still scope for a new generation of drugs to replace weight-loss market leaders like Novo Nordisk A/S’s Wegovy, ...

A new review highlights the future of anti-obesity medications that could outperform today's already blockbuster drugs like ...

The changes reflect “a cultural shift” around obesity medications, said Diana Zuckerman, president of the nonprofit National ...

A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...

The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.

Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss ...

Researchers are exploring whether microorganisms found in cow’s milk and soil can help prevent weight gain typically caused ...